Lactobacillus reuteri Composition for Urogenital Pathogen Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for urogenital tract infections, such as those caused by pathogens like Escherichia coli, Gardnerella vaginalis, and Candida species, often lead to the death of normal flora, promote drug-resistant pathogens, and cause undesirable side effects.
Innovation Solution
The use of Lactobacillus reuteri 3613 and Lactobacillus reuteri 3613-1 compositions, combined with adjuvants, carriers, or excipients, to reduce pathogen growth through pH regulation, reuterin production, and hydrogen peroxide generation, administered in various forms including food products and pharmaceuticals.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibiotic or anti-fungal medication is administered to treat urogenital tract infection, then pathogen growth is reduced, but normal flora is killed and drug-resistant pathogens are generated
Solution Approach 1:
Lactobacillus reuteri 3613 serves as a beneficial intermediary organism that competes with pathogenic microbes for resources and space in the urogenital tract. The probiotic bacterium produces antimicrobial substances and modifies the local environment to inhibit pathogen growth while preserving and restoring normal flora balance, thereby treating infection without the harmful side effects of conventional antibiotics
Solution Approach 2:
The invention changes the approach from direct pathogen killing to modifying ecological parameters of the urogenital tract. By introducing Lactobacillus reuteri 3613, the pH, oxygen levels, and nutrient availability are altered to favor beneficial bacteria and inhibit pathogenic organisms, achieving treatment through environmental parameter changes rather than direct antimicrobial action
2Reliability
If antibiotic or anti-fungal medication is administered to treat infection, then pathogen growth is reduced, but undesired side effects occur
Solution Approach 1:
Lactobacillus reuteri 3613 acts as a safe intermediary that restores natural microbial balance without causing the systemic side effects associated with broad-spectrum antibiotics. The probiotic selectively targets pathogenic organisms while supporting host health through production of beneficial metabolites and modulation of the local immune response
3Reliability
If conventional treatment is used to reduce pathogen growth, then infection is treated, but recurrent infections occur
Solution Approach 1:
The invention applies preliminary action by establishing a protective population of Lactobacillus reuteri 3613 in the urogenital tract before pathogenic organisms can establish themselves. This probiotic colonization creates long-term protective effects by continuously maintaining an environment unfavorable to pathogens, thereby preventing recurrence rather than merely treating acute episodes
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Effectively reduces pathogen growth by up to 99%, alleviates symptoms, and prevents infections without harming the normal flora, offering a safer alternative to antibiotics.
Implementation Method 1
reduce pathogen growth through pH regulation
Implementation Method 2
reduce pathogen growth through pH regulation, reuterin production
Implementation Method 3
reduce pathogen growth through pH regulation, reuterin production, and hydrogen peroxide generation
Data Source
AI summary
The present invention relates to microbial compositions containing Lactobacillus, and methods for reducing growth of microbes that cause infection, such as urogenital tract infection and for treating or preventing the same using the compositions thereof.